

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
June 24, 2021

**DRAFT MEETING ROSTER**

---

---

**DESIGNATED FEDERAL OFFICER (Non-Voting)**

**She-Chia Chen, PharmD**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Massimo Cristofanilli, MD, FACP**

Associate Director of Translational Research and  
Precision Medicine  
Robert H. Lurie Comprehensive Cancer Center  
Chicago, Illinois

**Jorge A. Garcia, MD, FACP**

Chair, Division of Solid Tumor Oncology  
George and Edith Richman Distinguished Scientist  
Chair  
Director, GU Oncology Program  
University Hospitals Seidman Cancer Center  
Case Comprehensive Cancer Center  
Case Western Reserve University  
Cleveland, Ohio

**Susan Halabi, PhD**

Professor of Biostatistics and Bioinformatics  
Duke University Medical Center  
Durham, North Carolina

**Philip C. Hoffman, MD**

*(Chairperson)*  
Professor of Medicine  
The University of Chicago  
Section of Hematology/Oncology  
Department of Medicine  
Chicago, Illinois

**Christopher H. Lieu, MD**

Associate Professor of Medicine  
Associate Director for Clinical Research  
Director, Gastrointestinal Medical Oncology Program  
University of Colorado  
Aurora, Colorado

**David E. Mitchell**

*(Consumer Representative)*  
Founder, Patients for Affordable Drugs  
Bethesda, Maryland

**Jorge J. Nieva, MD**

Associate Professor of Clinical Medicine  
Section Head, Solid Tumors  
University of Southern California (USC) Norris  
Comprehensive Cancer Center  
Keck School of Medicine of USC  
Los Angeles, California

**Ashley Rosko, MD**

Associate Professor  
Division of Hematology  
Department of Internal Medicine  
Medical Director, Oncogeriatric Program  
James Comprehensive Cancer Center  
The Ohio State University  
Columbus, Ohio

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***

June 24, 2021

**DRAFT MEETING ROSTER (cont.)**

---

---

**ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)**

**Albert L. Kraus, PhD**

*(Acting Industry Representative)*

Global Regulatory Portfolio Lead, Oncology  
Pfizer, Inc.  
Guilford, Connecticut

**TEMPORARY MEMBERS (Voting)**

**Neil Berlin**

*(Patient Representative)*

Owings Mills, Maryland

**Marcia Cruz-Correa, MD, PhD, AGAF, FASGE**

Professor, Medicine & Biochemistry  
Executive Director, University of Puerto Rico (UPR)  
Comprehensive Cancer Center  
UPR Medical Sciences Campus  
Puerto Rico Medical Center  
San Juan, Puerto Rico

**Pamela L. Kunz, MD**

Associate Professor  
Department of Medicine, Division of Oncology  
Yale University School of Medicine  
New Haven, Connecticut

**Mark A. Lewis, MD**

Director, Gastrointestinal Medical Oncology  
Intermountain Healthcare  
Murray, Utah

**Kathryn A. Lurain, MD**

Assistant Research Physician  
HIV and AIDS Malignancy Branch  
Center for Cancer Research  
National Cancer Institute  
National Institutes of Health  
Bethesda, Maryland

**Diane Reidy-Lagunes, MD**

Associate Attending Physician  
Memorial Hospital for Cancer & Allied Diseases  
New York, New York

**Kim Reiss Binder, MD**

Assistant Professor of Medicine  
Abramson Cancer Center  
University of Pennsylvania  
Perelman Center of Medicine  
Philadelphia, Pennsylvania

**Hanna K. Sanoff, MD, MPH**

Associate Professor, Division of Oncology  
Vice Chair for Clinical Operations  
Division of Oncology  
University of North Carolina  
Chapel Hill, North Carolina

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
June 24, 2021

**DRAFT MEETING ROSTER (cont.)**

---

---

**TEMPORARY MEMBERS (Voting Cont.)**

**Colin D. Weekes, MD, PhD, FASCO**

Associate Professor of Medicine  
Harvard Medical School  
Director, Medical Oncology Research for  
Pancreatic Cancer  
The Tucker Gosnell Center for  
Gastrointestinal Cancers  
Massachusetts General Hospital  
Boston, Massachusetts

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

Director, Oncology Center of Excellence (OCE)  
Director (Acting)  
Office of Oncologic Diseases (OOD)  
Office of New Drugs (OND), CDER, FDA

**Julia Beaver, MD**

Chief of Medical Oncology, OCE  
Deputy Director (Acting), OOD  
OND, CDER, FDA

**Paul Kluetz, MD**

Deputy Director, OCE  
Supervisory Associate Director for Clinical  
Oncology (Acting)  
OOD, OND, CDER, FDA

**Steven Lemery, MD, MHS**

Director (Acting)  
DO3, OOD, OND, CDER, FDA

**Lola Fashoyin-Aje, MD, MPH**

Associate Director for Science & Policy to  
Address Disparities (Acting), OCE  
Deputy Director (Acting)  
DO3, OOD, OND, CDER, FDA

**Sandra Casak, MD**

Team Leader (Acting)  
Division of Oncology 3 (DO3)  
OOD, OND, CDER, FDA

**May Tun Saung, MD**

Clinical Reviewer  
DO3, OOD, OND, CDER, FDA